Cingulate (CING) has named Nilay Patel, as Chief Legal Officer. Patel’s appointment comes as Cingulate plans to submit a new drug application to the FDA in coming weeks for its lead asset CTx-1301 for the treatment of Attention Deficit Hyperactivity Disorder. Patel brings more than two decades of legal and compliance leadership in the pharmaceutical industry, having advised companies across every stage of drug development, launch, and commercialization. He most recently served as Chief Legal Officer, Chief Compliance Officer and Corporate Secretary at Ironshore Pharmaceuticals. Before joining Ironshore, Patel held senior legal roles at Grifols, where he served as Assistant General Counsel for the company’s U.S. Bioscience division, and at Life Sciences Law , where he represented both emerging biotech firms and global pharmaceutical clients in licensing, mergers and acquisitions, and intellectual property matters.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CING:
- Cingulate Inc Approves Key Proposals at Annual Meeting
- Cingulate announces efficacy results from Phase 3 study of CTx-1301
- Cingulate price target lowered to $11 from $12 at Roth Capital
- Cingulate, Inc. Reports Increased Losses Amid R&D Expansion
- Cingulate receives formal pre-NDA meeting minutes from FDA for CTx-1301